NuVasive to Present at J.P. Morgan Healthcare Conference

NuVasive to Present at J.P. Morgan Healthcare Conference 
SAN DIEGO, CA -- (Marketwire) -- 01/02/13 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today that Alex Lukianov, Chairman of the Board and Chief Executive
Officer, is scheduled to present at the J.P. Morgan Healthcare
Conference at the Westin St. Francis Hotel located at 335 Powell
Street, San Francisco, CA, on Wednesday, January 9, 2013, at 9:00
a.m. PST.  
A live webcast of the J.P. Morgan presentation will be available
online from the investor relations page of the Company's corporate
website at www.nuvasive.com. After the live webcast, a replay of the
presentation will remain available on the website for 30 days.  
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. 
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines several
categories of solutions that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and safe,
easy reproducibility for the surgeon: a proprietary software-driven
nerve avoidance system and intra-operative monitoring support;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 75 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
risks and uncertainties are described in NuVasive's press releases
and periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange Commission
are available at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made. 
Contact:
Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
858-909-3394
investorrelations@nuvasive.com 
Investors:
Stephan Ogilvie
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com 
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.